SequelSEC

REGENERON PHARMACEUTICALS, INC. REGN

Pharmaceutical Preparations · CIK 0000872589 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$15.53B
Fiscal year ended 2026-06-30
Operating income
$3.84B
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

REGENERON PHARMACEUTICALS, INC. (REGN) reported revenue of $15.53B and net income of $4.33B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from REGENERON PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

REGENERON PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$15.53B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$3.84B
Net income$4.33B
Research & development$6.28B
Weighted-average diluted sharesUnavailable
Pretax income$5.17B
Income tax expense$837.30M
Diluted EPSUnavailable
Selling, general & administrative$2.74B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

REGENERON PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.46B
Total assets$41.73B
Current assets$18.45B
Total liabilities$10.02B
Current liabilities$5.53B
Total equity incl. NCI$31.71B
Temporary (mezzanine) equityUnavailable
Inventory$3.08B
Accounts receivable$6.57B
GoodwillUnavailable
Long-term debt$1.99B
Accounts payable$1.16B

Cash flow

REGENERON PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$4.68B
Capital expendituresUnavailable
Investing cash flow-$704.20M
Financing cash flow-$3.52B
Net change in cash$450.40M
Stock-based compensation$986.70M
Common dividends paid$378.50M
Common share repurchases$3.30B
Depreciation & amortization$528.60M

Derived

REGENERON PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin24.7%
FCF marginUnavailable
SBC / revenue6.4%
Current ratio3.34x
Revenue YoY growth9.3%
Net margin27.9%
R&D / revenue40.4%
CapEx / revenueUnavailable
Long-term debt / equity0.06x
Effective tax rate16.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open REGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-29View SEC filing
10-K · Filed 2026-02-04View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-08-01View SEC filing
10-Q · Filed 2025-04-29View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.